Kreft B P, Tanimoto A, Stark D D, Baba Y, Zhao L, Chen J T, Compton C C, Finn J P, Cavagna F M
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
J Magn Reson Imaging. 1993 Jan-Feb;3(1):41-9. doi: 10.1002/jmri.1880030109.
The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96%-248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.
在大鼠的四种不同实验性肿瘤模型中评估了肝细胞特异性造影剂钆贝葡胺（钆-双丙酯二葡甲胺）对肿瘤检测的效果。组织学结果与源自离体弛豫测量法和体内磁共振（MR）成像的定量数据相关。非浸润性肿瘤在给予造影剂后5至10分钟显示肝实质最大强化，并在接下来的30分钟内保持平稳。相比之下，导致肝细胞损伤和炎症变化的浸润性肿瘤使无肿瘤实质的最大强化延迟15至20分钟。非特异性肿瘤强化取决于肿瘤血管生成，且发生在给予造影剂后的早期阶段。尽管无肿瘤实质的特异性强化和非特异性肿瘤强化存在差异，但在静脉注射75 mmol/kg钆-双丙酯二葡甲胺30分钟后，所有肿瘤模型中的肿瘤-肝脏对比噪声比均增加了96%至248%。钆-双丙酯二葡甲胺增强了肿瘤的显影性，与肿瘤的组织学特征无关。
